Financing strengthens stability sheet and helps development of key growth initiatives
NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) — Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology firm centered on growing therapies concentrating on hypoxia and viral illnesses, right this moment introduced that it has accomplished a non-public placement financing on March 18, 2026, leading to gross proceeds of roughly $1.2 million.
In reference to the financing, the Firm issued an mixture of roughly 21,071,667 shares of its frequent inventory at a purchase order value of roughly $0.055 per share. Buyers additionally acquired warrants to buy as much as 19,750,001 extra shares of frequent inventory at an train value of $0.12 per share. The warrants have a time period of 5 years from the date of issuance.
The securities had been provided and offered in a non-public placement pursuant to an exemption from registration below Part 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. The securities haven’t been registered below the Securities Act and will not be provided or offered in america absent registration or an relevant exemption from registration necessities.
The Firm intends to make use of the web proceeds from the financing for working capital and basic company functions, together with advancing its growth packages and supporting chosen commercialization initiatives.
More Read
“This financing strengthens our balance sheet and supports the advancement of our clinical and development initiatives,” stated David Platt, PhD, Chief Govt Officer of Bioxytran. “In parallel, we are beginning to translate our galectin-targeting platform into commercial opportunities, including the market introduction of A-SUQAR®, our plant-derived dietary supplement expected to launch this quarter. This dual-track approach allows us to pursue near-term commercialization while continuing to advance our higher-value pharmaceutical programs.”
The warrants issued in reference to the financing present the potential for extra capital upon train, additional supporting the Firm’s long-term development plans.
About Bioxytran, Inc.
More Read
Bioxytran, Inc. is a biotechnology firm centered on the event of therapeutics concentrating on hypoxia-related circumstances and galectin-targeting carbohydrate applied sciences, with purposes throughout infectious viral illnesses, metabolic well being, and irritation. The corporate leverages proprietary applied sciences to handle vital unmet medical wants, with packages spanning pharmaceutical growth and choose business purposes.
Ahead-Wanting Statements
This press launch comprises forward-looking statements that contain dangers and uncertainties, together with statements concerning using proceeds, future growth plans, anticipated commercialization actions, and potential warrant workouts. Precise outcomes could differ materially from these projected attributable to varied components. Bioxytran undertakes no obligation to replace these statements besides as required by legislation.
For extra info, please go to:www.bioxytraninc.com
